Total Valuation
THC Therapeutics has a market cap or net worth of $24.16K. The enterprise value is $908.02K.
Market Cap$24.16K
Enterprise Value$908.02K
Share Statistics
THC Therapeutics has 40,266,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,266,148
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
THC Therapeutics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 20.42%.
Return on Equity (ROE)0.12
Return on Assets (ROA)-29.79
Return on Invested Capital (ROIC)20.42%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee0.00
Profits Per Employee-387.04K
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of THC Therapeutics is ―. THC Therapeutics’s PEG ratio is 0.00002.
PE Ratio―
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value>-0.01
Price to FCF>-0.01
Price to Operating Cash Flow-0.23
PEG Ratio0.00002
Income Statement
In the last 12 months, THC Therapeutics had revenue of 0.00 and earned -387.04K in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-1.39K
Operating Income-493.91K
Pretax Income-387.04K
Net Income-387.04K
EBITDA-492.52K
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -182.51K and capital expenditures 0.00, giving a free cash flow of -182.51K billion.
Operating Cash Flow-182.51K
Free Cash Flow-182.51K
Free Cash Flow per Share>-0.01
Dividends & Yields
THC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-43.88
52-Week Price Change-33.33%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)50.01K
Important Dates
THC Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
THC Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of -23.91%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap1.13K
Net Debt to EBITDA-1.61
Interest Coverage Ratio-6.21
Taxes
In the past 12 months, THC Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
THC Therapeutics EV to EBITDA ratio is -1.61, with an EV/FCF ratio of -9.27.
EV to Sales0.00
EV to EBITDA-1.61
EV to Free Cash Flow-9.27
EV to Operating Cash Flow-9.27
Balance Sheet
THC Therapeutics has $849.00 in cash and marketable securities with $731.79K in debt, giving a net cash position of -$730.94K billion.
Cash & Marketable Securities$849.00
Total Debt$731.79K
Net Cash-$730.94K
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for THC Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―